Navigation Links
Founders of Philadelphia Biotech Enterin Inc. Discover Link Between Upper GI Tract Infections and Parkinson's Disease

PHILADELPHIA, June 28, 2017 /PRNewswire/ -- Michael Zasloff, MD, Ph.D., Professor of Surgery and Pediatrics at Georgetown University School of Medicine, and Founder, Chairman and CEO of Enterin Inc. was the senior author of a study that has helped clarify the function of alpha-Synuclein (aS), the protein implicated in Parkinson's disease (PD) and other neurodegenerative diseases. Denise Barbut, MD, FRCP, Co-Founder, President and Chief Medical Officer of Enterin Inc. was senior co-author of the study.

Published in the Journal of Innate Immunity, the study finds that aS is released in response to an infection in the upper GI tract in children, inducing an immune response as part of the body's innate immune system. According to the researchers, these findings suggest that frequent or chronic upper GI infections could overwhelm the body's capacity to clear aS, ultimately leading to Parkinson's disease.

This research builds upon prior studies, which showed that the buildup of aS in PD patients actually begins in the enteric nervous system (nerves in the GI tract). Animal studies have further shown that microbes in the GI tract can induce formation of toxic aS aggregates in the enteric nervous system, which can then travel up to the brain.

The study showed a positive correlation between the expression of aS in enteric nerves of the upper GI tract and the degree of acute and chronic inflammation in the intestinal wall. Furthermore, the study showed that aS could potently attract immune cells such as macrophages and neutrophils, and could 'turn on' dendritic cells to alert the immune system of the specific pathogen encountered.

As Dr. Zasloff explains, "When expressed in normal amounts following an infection of the upper GI tract, aS is a good molecule. It is protective. The nervous system within the wall of the GI tract detects the presence of a pathogen and responds by releasing aS. aS then attracts white blood cells to the site where it has been released. In addition, aS produced in one nerve can spread to others with which it communicates thereby protecting a large field. By this means, the nervous system can protect both itself as well as the GI tract as a whole in the setting of an infection."

He adds, "It is well-known from animal studies that aS produced in the enteric nervous system can use the nerves connecting the GI tract to the brainstem as an escalator, trafficking aS from the gut to the brain and spreading to centers within the central nervous system. But too much aS — such as from multiple or chronic infections — becomes toxic because the system that disposes of aS is overwhelmed, nerves are damaged by the toxic aggregates that form and chronic inflammation ensues. Damage occurs both within the nervous system of the GI tract and the brain."

Dr. Zasloff says the new findings "make sense" of observations made in PD patients, such as the presence of chronic constipation from damage to the enteric nervous system that develops decades before brain symptoms become apparent and that chronic upper GI distress is relatively common in people who develop PD.

The publication of this study coincides with an ongoing Phase 1/2a clinical trial at 12 U.S. sites, sponsored by Enterin Inc., targeting the accumulation of aS in the enteric nervous system. The clinical trial is examining the safety, tolerability, pharmacokinetics, and pharmacodynamics of ENT-01 to relieve constipation associated with Parkinson's disease. Details of the RASMET study can be found on ENT-01 is an oral drug that contains a synthetic derivative of squalamine, a natural steroid made by the dogfish shark. Research recently published by Dr. Zasloff and collaborators demonstrated that squalamine both reduced the formation of toxic aS clumps and their toxicity, in animal models of Parkinson's disease.

About Enterin Inc.

Enterin Inc. is the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Enterin Inc. is pioneering the medical community's understanding of the link between infections, dysfunction of the enteric nervous system of the gut, and the early onset and chronic progression of neurodegenerative disease. The lead compound, ENT-01, displaces membrane-bound alpha-synuclein (aS) aggregates from nerve cells in the enteric nervous system and improves neural signaling between the gut and the brain in preclinical models of Parkinson's disease. In the gut, this results in improved motility. Enterin Inc. is now progressing ENT-01 through clinical trials aimed at reversing the constipation of Parkinson's disease. For more information, please visit

Enterin Inc.

Related Links


To view the original version on PR Newswire, visit:

SOURCE Enterin Inc.
Copyright©2017 PR Newswire.
All rights reserved

Related biology technology :

1. Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase
2. Founders Fund Backs Nanotronics Imaging
3. University of Pittsburgh and University City Science Center in Philadelphia Join Forces to Commercialize Early-Stage Technologies
4. New Orthopedic Device Technology Moves From Lab Toward Operating Room With Help From Philadelphia-Based Start-Up OrthoMend Research, Inc.
5. Early Stage Digital Health Companies In Philadelphia Get Boost With $6 Million Funding Initiative
6. PetroMar Technologies, Inc. Named to Philadelphia 100® for a Second Consecutive Year
7. ClinCapture Exhibits Booth 1648 at the Drug Information Association 52nd Annual Meeting in Philadelphia June 26-30, 2016
8. Advancing Insight Through Data Science: Join The Big Data & Analytics for Pharma Summit in Philadelphia Next Month
9. Wolf Administration Announces Biopharmaceutical Company Adaptimmune Therapeutics to Create 110 New Jobs in Philadelphia
10. Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA
11. Novogen to Present at Bio International Convention Philadelphia 2015
Post Your Comments:
(Date:7/25/2018)... ... July 25, 2018 , ... ... Innovator, joined the board of the Indiana India Business Council (IIBC), an advocacy ... today by the current board of directors, McDonald joins an impressive roster of ...
(Date:7/24/2018)... ... July 24, 2018 , ... Boval was founded in 1978 when ... suppliers. In Boval’s early days most of the BSA manufactured was for blood ... for diagnostic purposes after gel cards changed that market and displaced most of the ...
(Date:7/22/2018)... ... , ... Mitotech S.A, a Luxembourg based clinical stage biotechnology ... program in Dry Eye Disease. Under the agreement Essex Bio-Investment will fund U.S. ... first Phase 3 study starting as early as Fall 2018. , “We ...
(Date:7/22/2018)... ... 2018 , ... Today the Weed Science Society of America (WSSA) announced that ... is available on the Society’s website . The workshop was designed to identify ... manage factors contributing to dicamba off-target movement. , Dicamba herbicide has been ...
Breaking Biology Technology:
(Date:8/9/2018)... DALLAS (PRWEB) , ... August 09, 2018 , ... ... Inc. cell and viral gene therapy manufacturing facility has won Engineering News-Record (ENR) ... 121 entries were submitted for the Best Projects competition. The judges selected 42 ...
(Date:8/7/2018)... SOUTH JORDAN, Utah (PRWEB) , ... August 07, 2018 , ... ... collaboration solutions, announced today their new CT Cloud Voice and SIP solutions. CT ... a scalable and secure, quality voice solution that is far superior to traditional PBX ...
(Date:8/1/2018)... ... 01, 2018 , ... RURO, Inc., a company known for ... is the software framework that all of RURO’s products are built from, and ... and the future of RURO’s laboratory software portfolio. , To accommodate the needs ...
Breaking Biology News(10 mins):